Retour

SELLAS Life Sciences Group, Inc.

Qualité des données : 100%

SLS

NASDAQ Healthcare Biotechnology

5,48 €

▲ 0,72 € (15,13%)

Cap. Boursière : 780,58M

Fourchette du Jour

4,84 € 5,50 €

Fourchette 52 Semaines

0,95 € 6,14 €

Volume

9 916 235

Moyenne 50J / 200J

4,44 € / 2,54 €

Clôture Précédente

4,76 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (626 pairs)

Métrique	Action	Médiane du Secteur
P/E	-29,1	0,4
P/B	11,0	2,9
ROE %	-66,9	3,7
Net Margin %	—	3,9
Rev Growth 5Y %	—	10,0
D/E	0,0	0,2

Objectif de Cours des Analystes

Hold

2,80 € -48.9%

Low: 2,40 € High: 3,20 €

BPA Prévisionnel

-0,28 €

CA Est.

36 M

Estimations de Bénéfices

Période	BPA Est.	CA Est.	Analystes
FY2030	3,65 € 3,49 € – 3,81 €	580 M	1
FY2029	1,85 € 1,77 € – 1,93 €	320 M	1
FY2028	0,00 € -0,25 € – 0,30 €	120 M	3

Insider Trading Activity

14 transactions

Date	Insider	Type	Shares	Price	Value
Jan 7, 2026	Varian John Director	grant	50 000	—	—
Jan 7, 2026	Kalin Katherine Bach Director	grant	50 000	—	—
Jan 7, 2026	Wasman Jane Director	grant	50 000	—	—
Jan 7, 2026	Burns John Thomas CFO	grant	300 000	—	—
Jan 7, 2026	SCHEINBERG DAVID A Director	grant	50 000	—	—
Jan 7, 2026	CICIC DRAGAN SVP, Chief Development Officer	grant	300 000	—	—
Jan 7, 2026	VAN NOSTRAND ROBERT L Director	grant	50 000	—	—
Dec 3, 2025	CICIC DRAGAN SVP, Chief Development Officer	other	63 800	1,50 €	95 700 €
Dec 3, 2025	Burns John Thomas CFO	other	58 592	1,50 €	87 888 €
Dec 3, 2025	Stergiou Angelos M. President and CEO	other	187 066	1,50 €	280 599 €
Nov 19, 2025	Kalin Katherine Bach Director	buy	63 400	1,59 €	100 806 €
Jun 12, 2025	VAN NOSTRAND ROBERT L Director	buy	10 000	1,48 €	14 800 €
May 30, 2025	Wasman Jane Director	buy	20 000	1,69 €	33 800 €
May 22, 2025	Kalin Katherine Bach Director	buy	20 000	1,80 €	36 000 €

Points Clés

Debt/Equity of 0,01 — conservative balance sheet

Negative free cash flow of -28,39M

PEG of 0,31 suggests growth is underpriced

Croissance

Revenue Growth (5Y)

N/A

Revenue (1Y)N/A

Earnings (1Y)N/A

FCF Growth (3Y)N/A

Qualité

Return on Equity

-66,88%

ROIC-29,50%

Net MarginN/A

Op. MarginN/A

Sécurité

Debt / Equity

0,01

Current Ratio10,72

Interest Coverage0,00

Valorisation

P/E Ratio

-29,06

P/B Ratio11,01

EV/EBITDAN/A

Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y)	N/A	Revenue Growth (3Y)	N/A
Earnings Growth (1Y)	N/A	Earnings Growth (3Y)	N/A
Revenue Growth (5Y)	N/A	Earnings Growth (5Y)	N/A
Profitability
Revenue (TTM)	0,0	Net Income (TTM)	-26,86M
ROE	-66,88%	ROA	-34,29%
Gross Margin	N/A	Operating Margin	N/A
Net Margin	N/A	Free Cash Flow (TTM)	-28,39M
ROIC	-29,50%	FCF Growth (3Y)	N/A
Safety
Debt / Equity	0,01	Current Ratio	10,72
Interest Coverage	0,00	Dividend Yield	0,00%
Valuation
P/E Ratio	-29,06	P/B Ratio	11,01
P/S Ratio	N/A	PEG Ratio	0,31
EV/EBITDA	N/A	Dividend Yield	0,00%
Market Cap	780,58M	Enterprise Value	709,69M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Revenue	0,0	0,0	0,0	1,00M	7,60M
Net Income	-26,86M	-30,88M	-37,34M	-41,30M	-20,70M
EPS (Diluted)	-0,25	-0,50	-1,34	-2,13	-1,34
Gross Profit	0,0	0,0	0,0	900 000,0	7,40M
Operating Income	-28,27M	-31,51M	-37,87M	-41,95M	-25,29M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric	FY2025	FY2024	FY2023	FY2022	FY2021
Total Assets	78,35M	19,43M	6,22M	20,94M	26,43M
Total Liabilities	7,47M	9,97M	14,20M	16,09M	6,08M
Shareholders' Equity	70,87M	9,47M	-7,98M	4,85M	20,35M
Total Debt	1,00M	1,00M	906 000,0	945 000,0	808 000,0
Cash & Equivalents	71,89M	13,89M	2,53M	17,13M	21,46M
Current Assets	75,21M	16,33M	3,17M	17,76M	23,04M
Current Liabilities	7,02M	9,51M	13,74M	15,52M	4,98M